MLYS

SEC source: 0001933414-24-000062 · wk-form4_1734125816.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 146,008

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · derivative · entry 5

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 134,926

Underlying: Common Stock · 5,026 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 10,035

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · nonDerivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,991

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.05. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 146,017

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

SEC source: 0001933414-24-000061 · wk-form4_1731450331.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 140,991

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000052 · wk-form4_1731100892.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 139,952

Underlying: Common Stock · 25,482 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000052 · wk-form4_1731100892.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 135,974

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.19. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-24-000052 · wk-form4_1731100892.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 161,456

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

SEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 165,434

Underlying: Common Stock · 5,352 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 135,974

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000047 · wk-form4_1729023737.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 236,854

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.24 to $13.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 15,052

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000046 · wk-form4_1729023724.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 130,622

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000045 · wk-form4_1729023711.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 895,941

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $13.35 to $13.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 170,786

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 125,605

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 20,069

Underlying: Common Stock · 5,018 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000042 · wk-form4_1726173125.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 119,256

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 177,135

Underlying: Common Stock · 6,348 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 25,087

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 114,238

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000040 · wk-form4_1723580423.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 107,890

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001628280-24-033205 · wk-form4_1722044745.xml · nonDerivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Indirect · See Footnote

Disclosed balance after: 8,644,579

F1 · ownership.nature: Represents securities held directly by Catalys Pacific Fund, LP. The general partner of Catalys Pacific Fund, LP is Catalys Pacific Fund GP, LP. Brian Taylor Slingsby is the managing partner of Catalys Pacific, LLC, the general partner of the General Partner. Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby may be deemed to have voting and investment power over the shares held of record by Catalys Pacific Fund, LP. Each of Catalys Pacific, LLC, Catalys Pacific Fund GP, LP and Brian Taylor Slingsby disclaim beneficial ownership of such shares, except to the extent of any pecuniary interest therein.

SEC source: 0001628280-24-032253 · wk-form4_1721342039.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 183,483

Underlying: Common Stock · 525 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001628280-24-032253 · wk-form4_1721342039.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 102,873

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $15.00 to $15.01. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001628280-24-032253 · wk-form4_1721342039.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 103,398

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · kind: The transactions reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the reporting person on November 14, 2023.

SEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 184,008

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F4 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F5 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 102,873

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000034 · wk-form4_1720816673.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 247,611

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.93 to $13.43. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: This balance includes 2,906 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 30,104

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F2 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F3 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000035 · wk-form4_1720816738.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 96,524

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · balance_after: This balance includes 1,778 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-24-000033 · wk-form4_1720816599.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 911,212

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.96 to $13.76. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

SEC source: 0001933414-24-000032 · wk-form4_1718919832.xml · nonDerivative · entry 3

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 926,958

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.525 to $12.05.

SEC source: 0001933414-24-000032 · wk-form4_1718919832.xml · nonDerivative · entry 2

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 941,898

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $11.76 to $12.12.

SEC source: 0001933414-24-000032 · wk-form4_1718919832.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 958,505

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.0982 to $12.4627. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

SEC source: 0001933414-24-000029 · wk-form4_1718403341.xml · nonDerivative · entry 3

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 976,271

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F4 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.39 to $12.635.

SEC source: 0001933414-24-000029 · wk-form4_1718403341.xml · nonDerivative · entry 2

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 992,500

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F3 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.49 to $13.04.

SEC source: 0001933414-24-000031 · wk-form4_1718656394.xml · derivative · entry 1

Gold Alexander M · CIK 0002026429 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 44,000

Underlying: Common Stock · 44,000 shares

Expires 2034-06-13

F1 · derivative.exercise_date: The stock option vests in 36 monthly installments beginning on July 13, 2024.

SEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · derivative · entry 4

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 190,357

Underlying: Common Stock · 6,349 shares

Expires 2032-07-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F3 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $1.07 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F4 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on July 12, 2023, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · nonDerivative · entry 2

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 89,729

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000029 · wk-form4_1718403341.xml · nonDerivative · entry 1

Congleton Jon · CIK 0001644975 · Director · Chief Executive Officer

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 1,032,461

F1 · kind: The sales reported in this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on January 30, 2024.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.4587 to $13.35. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in footnotes (2), (3) and (4) to this Form 4.

SEC source: 0001933414-24-000027 · wk-form4_1718314405.xml · nonDerivative · entry 1

Levy Adam Scott · CIK 0001693134 · CFO and Secretary

10b5-1 filing: Plan reported

Ownership: Direct

Disclosed balance after: 255,462

F1 · kind: The sale reported in this Form 4 was effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person on November 14, 2023.

F2 · price: The price reported in Column 4 is a weighted-average price. These shares were sold in multiple transactions at prices ranging from $12.79 to $13.29. The Reporting Person undertakes to provide to the Issuer, any securityholder of the Issuer or the staff of the Securities and Exchange Commission, upon request, full information regarding the number of shares sold at each separate price within the ranges set forth in this footnote (2) to this Form 4.

F3 · balance_after: This balance includes 1,466 shares purchased under the Mineralys Therapeutics, Inc. 2023 Employee Stock Purchase Plan that were not previously reported.

SEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · derivative · entry 3

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 35,121

Underlying: Common Stock · 5,017 shares

Expires 2031-03-11

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

F1 · derivative.exercise_price: Due to a rounding error, the exercise price for this stock option was originally reported as $0.53 per share on the Reporting Person's Form 3 filed on February 9, 2023.

F2 · derivative.exercise_date: The stock option vested with respect to 25% of the underlying shares on March 12, 2022, and vests with respect to the remaining shares in 36 substantially equal monthly installments thereafter.

SEC source: 0001933414-24-000026 · wk-form4_1718314321.xml · nonDerivative · entry 1

Rodman David Malcom · CIK 0001672659 · Chief Medical Officer

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 83,380

Exercise/conversion can include RSU settlement. Transaction price and option strike are different fields; a missing price is not zero. Derivative and underlying rows can describe the same event.

SEC source: 0001933414-24-000020 · wk-form4_1716495678.xml · derivative · entry 1

Karydas Daphne · CIK 0001816952 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

SEC source: 0001933414-24-000021 · wk-form4_1716495693.xml · derivative · entry 1

AKKARAJU SRINIVAS · CIK 0001253170 · Director · 10% owner

Samsara BioCapital, L.P. · CIK 0001699737 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

SEC source: 0001933414-24-000022 · wk-form4_1716495708.xml · derivative · entry 1

SBLENDORIO GLENN · CIK 0001277478 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

SEC source: 0001933414-24-000019 · wk-form4_1716495657.xml · derivative · entry 1

Slingsby Brian Taylor · CIK 0001963901 · Director · 10% owner

Catalys Pacific Fund, LP · CIK 0001746274 · 10% owner

Joint disclosure: these amounts are not allocated separately to each reporting owner.

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.

SEC source: 0001933414-24-000023 · wk-form4_1716495741.xml · derivative · entry 1

DiRocco Derek · CIK 0001792061 · Director

10b5-1 filing: No plan indicated

Ownership: Direct

Disclosed balance after: 22,000

Underlying: Common Stock · 22,000 shares

Expires 2034-05-22

F1 · derivative.exercise_date: The stock option award vests in 12 substantially equal monthly installments beginning on June 22, 2024. In the event that the next annual meeting of stockholders occurs prior to May 22, 2025, any remaining unvested portion of the stock option award will vest on the date of such meeting.